-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 -- -- Significant unmet need with 5,000...
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE® (setmelanotide) to treat patients with Bardet-Biedl syndrome and...
-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS)‹ -- -- Recommendation based on...
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved...
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
#NAME?
Rhythm Pharmaceuticals has presented six-month data showing a reduction in weight and body mass index (BMI) from the long-term extension of the Phase II trial (NCT03651765) of Imcivree (setmelanotide) in patients with hypothalamic obesity.
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
#NAME?